Showing results (391-400 of 586) with videos related to

Sort By:
Pageof 59
Inorganic Chemistry|May 9, 2006
Thallophilic interactions in aryloxide compounds: the [Tl2(mu2-OAr)4] structural motif in (TlOAr)4 and Tl2Cu(OAr)4 compoundsMontana V Childress, David Millar, Todd M Alam, et al.
Journal of Clinical Pharmacology|November 28, 2017
The Effect of Food or Omeprazole on the Pharmacokinetics of Osimertinib in Patients With Non-Small-Cell Lung Cancer and in Healthy VolunteersKarthick Vishwanathan, Paul A Dickinson, Khanh Bui, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2015
Higher Risk of Infections with PI3K-AKT-mTOR Pathway Inhibitors in Patients with Advanced Solid Tumors on Phase I Clinical TrialsSaeed Rafii, Desamparados Roda, Elena Geuna, et al.
Biochemistry|April 10, 2024
4,4-Difluoroproline as a Unique 19F NMR Probe of Proline ConformationHimal K Ganguly, Brice A Ludwig, Caitlin M Tressler, et al.
ACS Omega|March 2, 2026
Synthesis, Characterization, and Cytotoxicity of Dicyclo-alkyl-amine-pyrophosphato-platinum​(II) ComplexesDianne M Wagner, Dieu Huyen My Nguyen, Emily McHenry, et al.
Gynecologic Oncology|June 15, 2020
Phase II study of pembrolizumab efficacy and safety in women with recurrent small cell neuroendocrine carcinoma of the lower genital tractMichael Frumovitz, Shannon N Westin, Gloria Salvo, et al.
BJU International|April 20, 2019
Long-term oncological outcomes of patients with paratesticular sarcomaHanan Goldberg, Lih-Ming Wong, Brendan Dickson, et al.
European Journal of Inorganic Chemistry|November 10, 2018
Deconvoluting the Innocent vs. Non-innocent Behavior of N,N-diethylphenylazothioformamide Ligands with Copper SourcesNicolas A Johnson, Samuel R Wolfe, Humayun Kabir, et al.
Cancer Chemotherapy and Pharmacology|August 9, 2018
A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumorsMary E R O'Brien, Debashis Sarker, Jaishree Bhosle, et al.
British Journal of Cancer|September 14, 2006
The multikinase inhibitor midostaurin (PKC412A) lacks activity in metastatic melanoma: a phase IIA clinical and biologic studyM J Millward, C House, D Bowtell, et al.
Pageof 59